Reza Ghiasvand is a postdoctoral fellow in the project "Beta-blockers; a novel class of drug targets to block melanoma progression?". Reza is a cancer epidemiologist, with a particular interest in causal relationships in skin cancer and breast cancer. He also works as a researcher at the Oslo Center for Biostatistics and Epidemiology, at Oslo University Hospital. In several projects on skin cancer he collaborates with the research group EpiStat (Epidemiological Studies of lifestyle and chronic diseases). He also has a collaboration with the QIMR Berghofer Medical Research Institute in Brisbane, Australia, where they investigates cancer recurrence after localized high-risk melanoma. Reza received his PhD from the Department of Biostatistics at the University of Oslo in cancer epidemiology and biostatistics in 2016.
Reza is a postdoctoral fellow in the project "Beta-blockers; a novel class of drug targets to block melanoma progression?". The project investigates the relationship between the use of prescribed beta-blockers and melanoma progression and mortality in the Norwegian population, using data from nationwide registries.
Reza also works as a researcher at the Oslo Center for Biostatistics and Epidemiology, at Oslo University Hospital.
In several projects on skin cancer he collaborates with the research group EpiStat (Epidemiological Studies of lifestyle and chronic diseases) at the Department of Biostatistics, University of Oslo.
He is also collaborating with the Queensland Cancer Control Analysis Team and with the Population and Cancer Studies Unit, QIMR Berghofer Medical Research Institute, Brisbane, Australia on the Primary Melanoma Prevention, a cohort study that examined recurrence after localized high-risk melanoma.
Reza is a cancer epidemiologist, with a particular interest in causal relationships in skin cancer and breast cancer.
Reza received his PhD from the Department of Biostatistics at the University of Oslo in cancer epidemiology and biostatistics in 2016.
He worked on melanoma risk factors using data from the Norwegian women and Cancer Study (NOWAC), a large prospective cohort study with more than 170,000 participants.
During his first postdoc (2016-2019), he continued to work on melanoma with more focus on heterogeneity and divergent etiological disease pathways.
